Cowen analyst Ken Cacciatore initiated coverage of scPharmaceuticals with an Outperform rating and $25 price target. scPharmaceuticals’ lead product, Furoscix, was approved in October and provides a subcutaneous treatment option to the 2M fluid overload episodes experienced by heart failure patients in need of IV diuretics, noted Cacciatore. His price target "conservatively" assumes peak Furoscix sales of $500M-plus by 2033-2034, or about 15% share of the addressable acute heart failure episodes, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SCPH:
- scPharmaceuticals initiated with an Outperform at Cowen
- scPharmaceuticals Announces Pricing of $50 Million Public Offering
- scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
- scPharmaceuticals to Participate in the Jefferies London Healthcare Conference
- scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022